TY - JOUR AU - Farkas, Katalin AU - Varga, Marina AU - Dinnyes, Izabella AU - Rem, Lili AU - Telkes, Gábor AU - Wágner, László József AU - Remport, Ádám AU - Piros, László AU - Szijártó, Attila AU - Huszty, Gergely TI - Low-Dose vs Standard-Dose Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplantation: A Single-Center Retrospective Analysis JF - TRANSPLANTATION PROCEEDINGS J2 - TRANSPLANT PROC VL - 56 PY - 2024 IS - 1 SP - 105 EP - 110 PG - 6 SN - 0041-1345 DO - 10.1016/j.transproceed.2023.11.021 UR - https://m2.mtmt.hu/api/publication/34501723 ID - 34501723 AB - Prophylactic administration of valganciclovir (VG) is an accepted method for the prevention of cytomegalovirus (CMV) infection after kidney transplantation (KTx). The standard dosage of oral VG is 900 mg/day, adjusted to renal function. There is growing evidence that low-dose 450 mg/day VG might be safe and effective. We compared low-dose vs standard-dose prophylaxis after KTx in a single-center follow-up study.Data from 603 renal transplantations at a single center were retrospectively analyzed (2011-2014, 12-month follow-up). Recipients with donor IgG positive-recipient IgG positive (D+/R+), (D+/R-), and (D-/R+) CMV serostatus were routinely treated with 450 mg/day VG for 3 months. Based on the same prophylactic dose, patients could be categorized into two groups according to their postoperative renal function: those receiving standard-dose VG due to a lower estimated glomerular filtration rate (eGFR) (average eGFR<60 mL/min/1.73 m2) and those receiving low-dose VG due to higher eGFR (average eGFR>60 mL/min/1.73 m2).Estimated glomerular filtration rate-based VG serum alterations significantly affected the risk of CMV infection with a higher incidence in higher VG levels (standard-dose: 357 patients, CMV: 33 cases (9.2 %); low-dose: 246 patients, CMV: 10 cases (4.1%). The occurrence of known risk factors: serologic risk distribution and rate of induction therapy were not statistically different between the 2 groups. Treatment of an acute rejection episode influenced the infection rate significantly in the standard-dose group. As a side effect of prophylaxis, leucopenia (<3G/L) was 2.46 times higher in standard-dose vs low-dose group.Low-dose VG administration is safe and non-inferior to the standard dose in the prophylaxis of CMV infection after KTx. LA - English DB - MTMT ER - TY - CHAP AU - Huszty, Gergely AU - Kóbori, László AU - Piros, László ED - Sándor, József TI - Transzplantációs alapismeretek T2 - Sebészet tankönyv és tudománytörténet: traumatológiai, szülészeti és urológiai alapismeretekkel kiegészítve PB - Semmelweis Kiadó és Multimédia Stúdió CY - Budapest SN - 9789633315910 PY - 2023 SP - 527 EP - 532 PG - 6 UR - https://m2.mtmt.hu/api/publication/34538815 ID - 34538815 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Huszty, Gergely AU - Igaz, Péter TI - Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered? JF - ENDOCRINE-RELATED CANCER J2 - ENDOCR-RELAT CANCER VL - 31 PY - 2023 IS - 1 SN - 1351-0088 DO - 10.1530/ERC-23-0220 UR - https://m2.mtmt.hu/api/publication/34422426 ID - 34422426 LA - English DB - MTMT ER - TY - JOUR AU - Huszty, Gergely AU - Bihari, László AU - Gráf, László AU - Szijártó, Attila AU - Máté, Szabolcs TI - A peritoneális felszín tumorainak sebészete – citoreduktív sebészet és hipertermiás intraperitoneális kemoterápia JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 67 PY - 2023 IS - 3 SP - 247 EP - 258 PG - 12 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/34167039 ID - 34167039 AB - Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been described decades ago. It has not became a widely practiced routine except in specialized centers - the complex technique, weakly standardized but resource demanding chemotherapy, lacking financial background and the many times questionable clinical benefit at a cost of high surgical load might have been the key factors. Refined technology, developing chemotherapy protocols together with growing clinical evidence are now more sharply delineating the range of indications where the procedure might be beneficial, increases survival, or is the only curative therapy. These include tumors of the appendix and pseudomyxoma peritonei, mesothelioma, and selected cases of ovarian, colorectal and gastric cancer. In addition to technical description of the intervention, we summarize the currently valid indications and describe our institutional protocol for the treatment of appendiceal malignancies. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Stark, Júlia AU - Tőke, Judit AU - Huszty, Gergely AU - Nagy, Péter AU - Bedics, Gábor AU - Bödör, Csaba AU - Tímár, József AU - Tóth, Miklós TI - Parathyroid cancer with MTOR gene mutation. Case report and review of the literature TS - Case report and review of the literature JF - ANNALES D ENDOCRINOLOGIE J2 - ANN ENDOCRINOL-PARIS VL - 84 PY - 2023 IS - 6 SP - 761 EP - 763 PG - 3 SN - 0003-4266 DO - 10.1016/j.ando.2023.06.003 UR - https://m2.mtmt.hu/api/publication/34081713 ID - 34081713 LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Gergely AU - Gerlei, Zsuzsanna AU - Haboub-Sandil, Anita AU - Görög, Dénes AU - Szabó, József AU - Kóbori, László AU - Huszty, Gergely AU - Bihari, László AU - Rózsa, Balázs AU - Pőcze, Balázs AU - Máthé, Zoltán AU - Piros, László TI - Optimizing Survival for Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Report and Current Perspectives JF - TRANSPLANTATION PROCEEDINGS J2 - TRANSPLANT PROC VL - 54 PY - 2022 IS - 9 SP - 2593 EP - 2597 PG - 5 SN - 0041-1345 DO - 10.1016/j.transproceed.2022.10.048 UR - https://m2.mtmt.hu/api/publication/33271361 ID - 33271361 AB - Hepatocellular carcinoma (HCC) is the leading primary liver tumor and a main indication for transplant. Transplant criteria are based on clinicopathologic features, meanwhile adequate downstaging and molecular mechanisms are getting more attention in evolving therapeutic algorithm of HCC. The aim of our study was to overview the results of the Hungarian Liver Transplant Program in the field of HCC and introduce new aspects of personalized treatment options.We performed retrospective analysis of survival and tumor recurrence of HCC-associated liver transplant recipients between October 2013 and December 2020. Patients were categorized in Milan criteria (MC), beyond MC but within University of California, San Francisco (UCSF), and beyond UCSF criteria groups after pathologic examination of the explanted liver. Demographic data and preoperative locoregional treatments were assessed.A total of 529 primer liver transplants were performed, 88 because of HCC. A total of 87 patients had underlying cirrhosis because of hepatitis C (54%), alcohol-related liver disease (33.7%), hepatitis B (4.5%), or unknown etiology. A total of 55.6% of the patients had at least one locoregional treatment. A total of 67.4% of the patients were within MC, 5.6% were within UCSF criteria, and 27% were beyond UCSF criteria. The 1-, 3-, and 5-year survival rates were 80%, 79%, and 75%. The outcome was better in early-stage tumors, but the difference was not significant (P = .745) CONCLUSIONS: The favorable survival in our department legitimates the strict transplant criteria of HCC. Adequate locoregional therapy as downstaging can expand recipient pool. Molecular tumor profiling may lead to personalized treatment of HCC. LA - English DB - MTMT ER - TY - JOUR AU - Meltzer, Anna Zsófia AU - Fintha, Attila AU - Cseprekál, Orsolya AU - Somogyi, Dóra AU - Szabó, József AU - Kóbori, László AU - Rózsa, Balázs AU - Piros, László AU - Huszty, Gergely TI - Graft Arterial Dissection and Thrombosis After Kidney Transplantation With Undiagnosed Fibromuscular Dysplasia From a Deceased Donor: Case Report and Review JF - TRANSPLANTATION PROCEEDINGS J2 - TRANSPLANT PROC VL - 54 PY - 2022 IS - 9 SP - 2603 EP - 2607 PG - 5 SN - 0041-1345 DO - 10.1016/j.transproceed.2022.10.049 UR - https://m2.mtmt.hu/api/publication/33257643 ID - 33257643 AB - Fibromuscular dysplasia (FMD), a relatively frequent arterial deformity with an estimated prevalence of 2% to 6% has been sporadically reported during deceased donor kidney donations. Only 8 case reports are available in the previous literature.In our work, implantation of 2 kidneys from the same deceased donor with macroscopically evident and later histologically confirmed FMD are presented, one of which ended up as acute arterial complication. Renal arteries were cut short to allow safe implantation, but arterial dissection and thrombosis led to graft loss in the early perioperative period in the latter case.Although resection of the arterial segments affected by FMD as a routine may allow implantation, macroscopically healthy-looking arteries might still be affected and thus carry elevated postoperative risk. The aim of our case report is to make proposal for an onsite diagnosis of FMD in case of clinical suspicion. LA - English DB - MTMT ER - TY - JOUR AU - Tőke, Judit AU - Uhlyarik, Andrea AU - Lohinszky, Júlia AU - Stark, Júlia AU - Huszty, Gergely AU - Micsik, Tamás AU - Borka, Katalin AU - Reismann, Péter AU - Horányi, János AU - Igaz, Péter AU - Tóth, Miklós TI - Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series JF - FRONTIERS IN ENDOCRINOLOGY J2 - FRONT ENDOCRINOL VL - 13 PY - 2022 PG - 11 SN - 1664-2392 DO - 10.3389/fendo.2022.952418 UR - https://m2.mtmt.hu/api/publication/33153589 ID - 33153589 N1 - Department of Internal Medicine and Oncology, European Reference Network on Rare Endocrine Conditions (ENDO-ERN), Health Care Provider (HCP), Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Internal Medicine and Haematology, Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Surgery, Transplantation and Gastroenterology, Faculty of Medicine, Semmelweis University, Budapest, Hungary First Department of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Endocrinology, European Network for the Study of Adrenal Tumours (ENS@T) Research Center of Excellence, Faculty of Medicine, Semmelweis University, Budapest, Hungary Magyar Tudományos Akadémia-Semmelweis Egyetem (MTA-SE) Molecular Medicine Research Group, Eötvös Loránd Research Network, Budapest, Hungary Cited By :1 Export Date: 3 April 2023 Correspondence Address: Tóth, M.; Department of Internal Medicine and Oncology, Hungary; email: toth.miklos@med.semmelweis-univ.hu AB - ObjectivesThis study aimed to characterise the clinicopathological features and prognostic factors of a large cohort of Hungarian patients with adrenocortical cancer diagnosed between 2000-2021.Patients and methodsThis retrospective study included seventy-four patients (27 men and 47 women) with histologically confirmed adrenocortical cancer in a single tertiary referral endocrine centre. Descriptive statistics were performed, providing summaries of selected clinical and pathological parameters. Clinicopathological factors contributing to overall survival were analysed.ResultsThe median age of patients was 48,5 years (17-84 years) at diagnosis. The majority of cases were diagnosed at ENSAT stage II (39,2%) and stage IV (33,8%). At diagnosis, the median tumour size was 9,0 cm (4,5-20 cm). In 47 patients (71,6%), the tumour was hormonally active. The median overall survival and the 5-year survival rate were 23,5 months (95% CI, 17-30,5 months) and 18,3%, respectively. Primary tumour resection was performed in 68 patients (91,8%); R0 surgical resection was achieved in 30 patients. In univariate Cox regression model, tumours with stages III and IV, high proliferative activity (Ki67-index > 10%), R1-R2 surgical resection state and hormonal activity were associated with poorer survival. Cortisol excess, both isolated and combined with androgen production, was associated with poorer survival. Fifty-five patients were treated with mitotane. The overall survival of patients achieving therapeutic mitotane plasma concentration was significantly better compared to those who never reached it [27.0 (2-175) months vs 18.0 (2-83) months; p<0.05)]. The median age, the distribution of gender, ENSAT stage, resection state and Ki67-index did not differ between these two groups. The time needed to reach the therapeutic range of serum mitotane was 96.5 days (95% CI, 75-133 days).ConclusionOur results confirm previous data that disease stage, mitotic activity, the resection state and the mitotane treatment achieving therapeutic concentration are the most critical parameters influencing the prognosis of adrenocortical cancer. Our data suggest that hormonal activity may be more frequent than described previously, and it is a strong and independent prognostic factor of overall survival. To our knowledge, this is the first single-centre study confirming the prognostic importance of achieving therapeutic mitotane concentration. LA - English DB - MTMT ER - TY - GEN AU - Farkas, Katalin AU - Huszty, Gergely AU - Varga, Marina AU - Telkes, Gábor AU - Cseprekál, Orsolya AU - Marton, Adrienn AU - Dinnyés, Izabella AU - Rem, Lili AU - Szijártó, Attila TI - CMV profilaxis alacsony dózisú valganciclovirrel vesetranszplantáció után PY - 2022 UR - https://m2.mtmt.hu/api/publication/33105564 ID - 33105564 N1 - [előadás] LA - Hungarian DB - MTMT ER - TY - JOUR AU - Igaz, Péter AU - Toth, Geza AU - Nagy, Péter AU - Dezső, Katalin AU - Turai, Péter István AU - Medvecz, Márta AU - Wikonkál, Norbert AU - Huszty, Gergely AU - Piros, László AU - Tóth, Erika AU - Bozsik, Anikó AU - Likó, István AU - Patócs, Attila Balázs AU - Butz, Henriett TI - Surprising genetic and pathological findings in a patient with giant bilateral periadrenal tumours: PEComas and mutations of PTCH1 in Gorlin-Goltz syndrome JF - JOURNAL OF MEDICAL GENETICS J2 - JMG VL - 59 PY - 2022 IS - 9 SP - 916 EP - 919 PG - 4 SN - 0022-2593 DO - 10.1136/jmedgenet-2021-108082 UR - https://m2.mtmt.hu/api/publication/32545013 ID - 32545013 N1 - Funding Agency and Grant Number: Hungarian National Research, Development and Innovation Office (NKFIH) grantsNational Research, Development & Innovation Office (NRDIO) - Hungary [K134215, K125231]; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary of the Semmelweis University; Bolyai Research Fellowship of the Hungarian Academy of SciencesHungarian Academy of Sciences; National Laboratories Excellence programme (National Tumorbiology Laboratory project) [NLP-17] Funding text: Hungarian National Research, Development and Innovation Office (NKFIH) grants K134215 to PI and K125231 to AP. The study was also financed by the Higher Education Institutional Excellence Program-of the Ministry of Human Capacities in Hungary, within the framework of the molecular biology thematic programme of the Semmelweis University. HB is a recipient of Bolyai Research Fellowship of the Hungarian Academy of Sciences. AP and HB acknowledge financial support from the National Laboratories Excellence programme (under the National Tumorbiology Laboratory project (NLP--17)). LA - English DB - MTMT ER -